{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:55:33Z","timestamp":1792569333617,"version":"4.5.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"3","funder":[{"DOI":"10.13039\/100000005","name":"DoD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007188","name":"the Uniformed Services University of the Health Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003896","name":"HJF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003896","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["Y1-AI-5072"],"award-info":[{"award-number":["Y1-AI-5072"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HU0001190002"],"award-info":[{"award-number":["HU0001190002"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000098","name":"National Institutes of Health Clinical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019346","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["75N91019D00024"],"award-info":[{"award-number":["75N91019D00024"]}],"id":[{"id":"10.13039\/100019346","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019346","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["75N91019F00130"],"award-info":[{"award-number":["75N91019F00130"]}],"id":[{"id":"10.13039\/100019346","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019346","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["W81XWH-18\u20132\u20130040"],"award-info":[{"award-number":["W81XWH-18\u20132\u20130040"]}],"id":[{"id":"10.13039\/100019346","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019346","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["HT9425\u201324\u20133\u20130004"],"award-info":[{"award-number":["HT9425\u201324\u20133\u20130004"]}],"id":[{"id":"10.13039\/100019346","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Viral blips have been associated with larger reservoir size and slower decay. Earlier antiretroviral therapy (ART) initiation may decrease the risk of blips.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We analyzed participants from the US Military HIV Natural History Study with an estimated human immunodeficiency virus (HIV) seroconversion date, viral suppression \u2264400\u2005copies\/mL within 1 year after starting ART, and at least 3 HIV RNA measurements after suppression. A blip was defined as HIV RNA 401\u20131000\u2005copies\/mL preceded and followed by HIV RNA \u2264400\u2005copies\/mL without changing ART. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for factors potentially associated with the time from viral suppression to first blip.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>From 1996 through 2022, among 1413 participants on stable suppressive ART, 88 (6.2%) had at least one blip, including 68 (77.3%) with only a single blip. The overall incidence was 1.2 blips per 100 person-years (95% CI: .9\u20131.4). In multivariable modeling, ART initiation within 24 months of estimated HIV acquisition was independently associated with decreased hazard of viral blips compared with ART initiation after more than 24 months (0\u20136 months HR: 0.29 and 95% CI: .18\u2013.48; 6\u201312 months HR: 0.43 and 95% CI: .31\u2013.59; 12\u201324 months HR: 0.46 and 95% CI: .35\u2013.60).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Participants who initiated ART within 2 years of HIV acquisition had lower hazard of blips, potentially reflecting smaller reservoir size and suggesting reservoir plasticity that extends beyond the acute phase of HIV.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciaf103","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T04:15:34Z","timestamp":1741580134000},"page":"499-509","source":"Crossref","is-referenced-by-count":7,"title":["Antiretroviral Therapy Within 2 Years of HIV Acquisition Is Associated With Fewer Viral Blips: A Retrospective Analysis of More Than 20 Years of Data From the US Military HIV Natural History Study"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5947-265X","authenticated-orcid":false,"given":"Trevor A","family":"Crowell","sequence":"first","affiliation":[{"name":"US Military HIV Research Program, Center for Infectious Disease Research, Walter Reed Army Institute of Research , Silver Spring, Maryland ,","place":["USA"]},{"name":"Global Infectious Diseases, Henry M. Jackson Foundation for the Advancement of Military Medicine , Bethesda, Maryland ,","place":["USA"]},{"name":"Department of Medicine, Uniformed Services University of the Health Sciences , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsing-Chuan","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Global Infectious Diseases, Henry M. Jackson Foundation for the Advancement of Military Medicine , Bethesda, Maryland ,","place":["USA"]},{"name":"Department of Medicine, Uniformed Services University of the Health Sciences , Bethesda, Maryland ,","place":["USA"]},{"name":"Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0330-9473","authenticated-orcid":false,"given":"Xun","family":"Wang","sequence":"additional","affiliation":[{"name":"Global Infectious Diseases, Henry M. Jackson Foundation for the Advancement of Military Medicine , Bethesda, Maryland ,","place":["USA"]},{"name":"Department of Medicine, Uniformed Services University of the Health Sciences , Bethesda, Maryland ,","place":["USA"]},{"name":"Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2628-290X","authenticated-orcid":false,"given":"Xiuping","family":"Chu","sequence":"additional","affiliation":[{"name":"Global Infectious Diseases, Henry M. Jackson Foundation for the Advancement of Military Medicine , Bethesda, Maryland ,","place":["USA"]},{"name":"Department of Medicine, Uniformed Services University of the Health Sciences , Bethesda, Maryland ,","place":["USA"]},{"name":"Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britt","family":"Gayle","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Center for Infectious Disease Research, Walter Reed Army Institute of Research , Silver Spring, Maryland ,","place":["USA"]},{"name":"Global Infectious Diseases, Henry M. Jackson Foundation for the Advancement of Military Medicine , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5655-8183","authenticated-orcid":false,"given":"Catherine M","family":"Berjohn","sequence":"additional","affiliation":[{"name":"Department of Medicine, Uniformed Services University of the Health Sciences , Bethesda, Maryland ,","place":["USA"]},{"name":"Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences , Bethesda, Maryland ,","place":["USA"]},{"name":"Naval Medical Center San Diego , San Diego, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4942-5826","authenticated-orcid":false,"given":"Jason M","family":"Blaylock","sequence":"additional","affiliation":[{"name":"Infectious Disease Service, Walter Reed National Military Medical Center , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M","family":"Yabes","sequence":"additional","affiliation":[{"name":"Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences , Bethesda, Maryland ,","place":["USA"]},{"name":"Brooke Army Medical Center , San Antonio, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6147-7182","authenticated-orcid":false,"given":"Derek T","family":"Larson","sequence":"additional","affiliation":[{"name":"Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences , Bethesda, Maryland ,","place":["USA"]},{"name":"Naval Medical Center San Diego , San Diego, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H","family":"Powers","sequence":"additional","affiliation":[{"name":"Clinical Research Directorate, Frederick National Laboratory for Cancer Research , Frederick, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8901-1432","authenticated-orcid":false,"given":"Robert J","family":"O\u2019Connell","sequence":"additional","affiliation":[{"name":"Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Ganesan","sequence":"additional","affiliation":[{"name":"Global Infectious Diseases, Henry M. Jackson Foundation for the Advancement of Military Medicine , Bethesda, Maryland ,","place":["USA"]},{"name":"Department of Medicine, Uniformed Services University of the Health Sciences , Bethesda, Maryland ,","place":["USA"]},{"name":"Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5114-1669","authenticated-orcid":false,"given":"Brian K","family":"Agan","sequence":"additional","affiliation":[{"name":"Global Infectious Diseases, Henry M. Jackson Foundation for the Advancement of Military Medicine , Bethesda, Maryland ,","place":["USA"]},{"name":"Department of Medicine, Uniformed Services University of the Health Sciences , Bethesda, Maryland ,","place":["USA"]},{"name":"Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Infectious Disease Clinical Research Program HIV Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Bettger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Markelz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Mende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Merritt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Merritt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Sjoberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Schofield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Powers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Banks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Joya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Lalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Tant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Kirkland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Krauth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Wisniewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Copeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Ewers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Parmelee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Schvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Tribble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Waggoner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Peel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Barahona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Custer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Decker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Justin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Paalzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Ressner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"2025100602574721500_ciaf103-B1","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/infdis\/jis104","article-title":"Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis","volume":"205","author":"Grennan","year":"2012","journal-title":"J Infect Dis"},{"key":"2025100602574721500_ciaf103-B2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/QAI.0b013e31819e721b","article-title":"Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the TaqMan assay in comparison to the Amplicor assay","volume":"51","author":"Lima","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025100602574721500_ciaf103-B3","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jcv.2011.12.024","article-title":"Comparison of the rate and size of HIV-1 viral load blips with Roche COBAS TaqMan HIV-1 versions 1.0 and 2.0 and implications for patient management","volume":"53","author":"Garrett","year":"2012","journal-title":"J Clin Virol"},{"key":"2025100602574721500_ciaf103-B4","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1471-2334-12-100","article-title":"HIV-1 low-level viraemia assessed with 3 commercial real-time PCR assays show high variability","volume":"12","author":"Ruelle","year":"2012","journal-title":"BMC Infect Dis"},{"key":"2025100602574721500_ciaf103-B5","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1080\/09540121.2020.1806198","article-title":"Low-level HIV viremia is associated with low antiretroviral prescription refill rates and social deprivation","volume":"33","author":"Goupil de Bouille","year":"2021","journal-title":"AIDS Care"},{"key":"2025100602574721500_ciaf103-B6","doi-asserted-by":"crossref","first-page":"ofab463","DOI":"10.1093\/ofid\/ofab463","article-title":"Low-level viremia is associated with cumulative adherence to antiretroviral therapy in persons with HIV","volume":"8","author":"Castillo-Mancilla","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2025100602574721500_ciaf103-B7","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1097\/QAD.0000000000002967","article-title":"Use of dietary supplements containing polyvalent cations and antacids among people with HIV and its impact on viral suppression","volume":"35","author":"Peng","year":"2021","journal-title":"Aids"},{"key":"2025100602574721500_ciaf103-B8","doi-asserted-by":"crossref","first-page":"e1000533","DOI":"10.1371\/journal.pcbi.1000533","article-title":"Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy","volume":"5","author":"Rong","year":"2009","journal-title":"PLoS Comput Biol"},{"key":"2025100602574721500_ciaf103-B9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jtbi.2014.06.042","article-title":"Stochastic population switch may explain the latent reservoir stability and intermittent viral blips in HIV patients on suppressive therapy","volume":"360","author":"Wang","year":"2014","journal-title":"J Theor Biol"},{"key":"2025100602574721500_ciaf103-B10","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1097\/QAD.0000000000003001","article-title":"HIV-1 viral blips are associated with repeated and increasingly high levels of cell-associated HIV-1 RNA transcriptional activity","volume":"35","author":"Suzuki","year":"2021","journal-title":"Aids"},{"key":"2025100602574721500_ciaf103-B11","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1038\/s41467-019-10884-9","article-title":"Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART","volume":"10","author":"Bachmann","year":"2019","journal-title":"Nat Commun"},{"key":"2025100602574721500_ciaf103-B12","doi-asserted-by":"crossref","first-page":"13193","DOI":"10.1073\/pnas.94.24.13193","article-title":"Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy","volume":"94","author":"Chun","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025100602574721500_ciaf103-B13","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","article-title":"Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy","volume":"278","author":"Finzi","year":"1997","journal-title":"Science"},{"key":"2025100602574721500_ciaf103-B14","doi-asserted-by":"crossref","first-page":"eaav3491","DOI":"10.1126\/scitranslmed.aav3491","article-title":"Abundant HIV-infected cells in blood and tissues are rapidly cleared upon ART initiation during acute HIV infection","volume":"12","author":"Leyre","year":"2020","journal-title":"Sci Transl Med"},{"key":"2025100602574721500_ciaf103-B15","doi-asserted-by":"crossref","first-page":"e01519","DOI":"10.1128\/JVI.01519-19","article-title":"Intact HIV proviruses persist in children seven to nine years after initiation of antiretroviral therapy in the first year of life","volume":"94","author":"Katusiime","year":"2020","journal-title":"J Virol"},{"key":"2025100602574721500_ciaf103-B16","doi-asserted-by":"publisher","first-page":"e33948","DOI":"10.1371\/journal.pone.0033948","article-title":"Impact of multi-targeted antiretroviral treatment on Gut T cell depletion and HIV reservoir seeding during acute HIV infection.","volume":"7","author":"Ananworanich","year":"2012","journal-title":"PLoS One"},{"key":"2025100602574721500_ciaf103-B17","doi-asserted-by":"crossref","first-page":"9523","DOI":"10.1073\/pnas.1120248109","article-title":"Immediate antiviral therapy appears to restrict resting CD4 + cell HIV-1 infection without accelerating the decay of latent infection","volume":"109","author":"Archin","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025100602574721500_ciaf103-B18","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/jac\/dkv084","article-title":"Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission","volume":"70","author":"Cheret","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2025100602574721500_ciaf103-B19","doi-asserted-by":"crossref","first-page":"e1003211","DOI":"10.1371\/journal.ppat.1003211","article-title":"Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study","volume":"9","author":"Saez-Cirion","year":"2013","journal-title":"PLoS pathogens"},{"key":"2025100602574721500_ciaf103-B20","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3851\/IMP2273","article-title":"HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy","volume":"17","author":"Goujard","year":"2012","journal-title":"Antivir Ther"},{"key":"2025100602574721500_ciaf103-B21","doi-asserted-by":"crossref","first-page":"e1001196","DOI":"10.1371\/journal.pmed.1001196","article-title":"No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial","volume":"9","author":"Grijsen","year":"2012","journal-title":"PLoS Med"},{"key":"2025100602574721500_ciaf103-B22","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1001\/archinternmed.2012.2719","article-title":"Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion","volume":"172","author":"Lodi","year":"2012","journal-title":"Arch Intern Med"},{"key":"2025100602574721500_ciaf103-B23","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1093\/cid\/ciz936","article-title":"Viral blips after treatment initiation during acute human immunodeficiency virus infection","volume":"70","author":"Crowell","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025100602574721500_ciaf103-B24","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/cid\/ciw683","article-title":"Persistent, albeit reduced, chronic inflammation in persons starting antiretroviral therapy in acute HIV infection","volume":"64","author":"Sereti","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2025100602574721500_ciaf103-B25","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12977-018-0458-6","article-title":"Reduction of inflammation and T cell activation after 6 months of cART initiation during acute, but not in early chronic HIV-1 infection","volume":"15","author":"de Paula","year":"2018","journal-title":"Retrovirology"},{"key":"2025100602574721500_ciaf103-B26","volume-title":"Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach","author":"World Health Organization","year":"16  2021"},{"key":"2025100602574721500_ciaf103-B27","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents"},{"key":"2025100602574721500_ciaf103-B28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA Panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"2025100602574721500_ciaf103-B29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12981-019-0240-4","article-title":"Leveraging early HIV diagnosis and treatment in Thailand to conduct HIV cure research","volume":"16","author":"Muccini","year":"2019","journal-title":"AIDS Res Ther"},{"key":"2025100602574721500_ciaf103-B30","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1001\/jama.2019.6587","article-title":"Screening for HIV infection: US Preventive Services Task Force recommendation statement","volume":"321","author":"US Preventive Services Task Force","year":"2019","journal-title":"JAMA"},{"key":"2025100602574721500_ciaf103-B31","doi-asserted-by":"crossref","first-page":"830","DOI":"10.15585\/mmwr.mm6631a3","article-title":"Recommendations for HIV screening of gay, bisexual, and other men who have sex with men\u2014United States, 2017","volume":"66","author":"DiNenno","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"RR-14","key":"2025100602574721500_ciaf103-B32","first-page":"1","article-title":"Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings","volume":"55","author":"Branson","year":"2006","journal-title":"MMWR Recomm Rep"},{"key":"2025100602574721500_ciaf103-B33","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1001\/jama.2019.6390","article-title":"Preexposure prophylaxis for the prevention of HIV infection: US Preventive Services Task Force recommendation statement","volume":"321","author":"US Preventive Services Task Force","year":"2019","journal-title":"JAMA"},{"key":"2025100602574721500_ciaf103-B34","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1056\/NEJM198906153202403","article-title":"Direct measurement of human immunodeficiency virus seroconversions in a serially tested population of young adults in the United States Army, October 1985 to October 1987. Walter Reed Retrovirus Research Group","volume":"320","author":"McNeil","year":"1989","journal-title":"N Engl J Med"},{"key":"2025100602574721500_ciaf103-B35","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1001\/jama.1991.03460130101030","article-title":"Trends of HIV seroconversion among young adults in the US Army, 1985 to 1989. US Army Retrovirus Research Group","volume":"265","author":"McNeil","year":"1991","journal-title":"JAMA"},{"key":"2025100602574721500_ciaf103-B36","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/QAI.0000000000002898","article-title":"Lower incidence of HIV-1 blips observed during integrase inhibitor-based combination antiretroviral therapy","volume":"89","author":"Dijkstra","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025100602574721500_ciaf103-B37","doi-asserted-by":"crossref","first-page":"ofz177","DOI":"10.1093\/ofid\/ofz177","article-title":"INSTI-based triple regimens in treatment-naive HIV-infected patients are associated with HIV-RNA viral load suppression at ultralow levels","volume":"6","author":"Lambert-Niclot","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2025100602574721500_ciaf103-B38","doi-asserted-by":"crossref","first-page":"eaaw5589","DOI":"10.1126\/scitranslmed.aaw5589","article-title":"The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation","volume":"11","author":"Abrahams","year":"2019","journal-title":"Sci Transl Med"},{"key":"2025100602574721500_ciaf103-B39","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jcv.2017.03.018","article-title":"Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA","volume":"91","author":"Rossetti","year":"2017","journal-title":"J Clin Virol"},{"key":"2025100602574721500_ciaf103-B40","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1097\/QAD.0b013e32833d214c","article-title":"Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen","volume":"24","author":"Delaugerre","year":"2010","journal-title":"Aids"},{"key":"2025100602574721500_ciaf103-B41","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/cid\/ciy1095","article-title":"Switching from a protease inhibitor-based regimen to a dolutegravir-based regimen: a randomized clinical trial to determine the effect on peripheral blood and ileum biopsies from antiretroviral therapy-suppressed human immunodeficiency virus-infected individuals","volume":"69","author":"Moron-Lopez","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025100602574721500_ciaf103-B42","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1086\/523704","article-title":"Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia","volume":"196","author":"Podsadecki","year":"2007","journal-title":"J Infect Dis"},{"key":"2025100602574721500_ciaf103-B43","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1097\/QAD.0000000000001443","article-title":"Demographics and natural history of HIV-1-infected spontaneous controllers of viremia","volume":"31","author":"Yang","year":"2017","journal-title":"Aids"},{"key":"2025100602574721500_ciaf103-B44","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00430-010-0172-z","article-title":"Prevalence and characteristics of hepatitis B and C virus infections in treatment-naive HIV-infected patients","volume":"200","author":"Reuter","year":"2011","journal-title":"Med Microbiol Immunol"},{"key":"2025100602574721500_ciaf103-B45","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S2055-6640(20)30689-0","article-title":"Factors associated with HIV RNA viral loads in ART-naive patients: implications for treatment as prevention in concentrated epidemics","volume":"2","author":"Rangarajan","year":"2016","journal-title":"J Virus Erad"},{"key":"2025100602574721500_ciaf103-B46","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1128\/JCM.02461-13","article-title":"Comparative performances of HIV-1 RNA load assays at low viral load levels: results of an international collaboration","volume":"52","author":"Swenson","year":"2014","journal-title":"J Clin Microbiol"},{"key":"2025100602574721500_ciaf103-B47","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1128\/JCM.00801-15","article-title":"Comparison of three different FDA-approved plasma HIV-1 RNA assay platforms confirms the virologic failure endpoint of 200 copies per milliliter despite improved assay sensitivity","volume":"53","author":"Lalama","year":"2015","journal-title":"J Clin Microbiol"},{"key":"2025100602574721500_ciaf103-B48","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3851\/IMP3128","article-title":"Viral blips were infrequent in treatment-naive adults treated with rilpivirine\/emtricitabine\/tenofovir DF or efavirenz\/emtricitabine\/tenofovir DF through 96 weeks","volume":"22","author":"Porter","year":"2017","journal-title":"Antivir Ther"},{"key":"2025100602574721500_ciaf103-B49","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1186\/s12879-015-1120-8","article-title":"Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV cohort study","volume":"15","author":"Young","year":"2015","journal-title":"BMC Infect Dis"},{"key":"2025100602574721500_ciaf103-B50","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/QAD.0000000000003881","article-title":"Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: results from a multinational clinical trial","volume":"38","author":"Crowell","year":"2024","journal-title":"Aids"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf103\/62361470\/ciaf103.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/3\/499\/62361470\/ciaf103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/3\/499\/62361470\/ciaf103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:57:57Z","timestamp":1759733877000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/81\/3\/499\/8067389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,10]]},"published-print":{"date-parts":[[2025,10,6]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf103","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9,15]]},"published":{"date-parts":[[2025,3,10]]}}}